Vemlidy is now approved to treat patients 6 years and older with chronic hepatitis B virus infection.
The FDA has expanded the indication of Vemlidy (tenofovir alafenamide) for patients with chronic hepatitis B virus (HBV) infection. It now approved to treat pediatric patients 6 years of age and older and weighing at least 25 kg. Vemlidy is already available to treat adults and adolescents 12 years and older.
Hepatitis B (HBV) is a serious disease that attacks the liver and can cause chronic infection, cirrhosis of the liver, liver cancer, and death in up to a third of patients. Hepatitis B is spread through infected blood or body fluids, sexual contact, injection drug use, or perinatally from mother to child.
“Chronic hepatitis B can have a significant and lasting impact on the health of children. If left untreated, hepatitis B can lead to liver cirrhosis and liver cancer,” Chaun-Hao Lin, M.D., Associate Professor of Clinical Pediatrics Krek School of Medicine of USC, said in a news release.
Developed by Gilead Sciences, Vemlidy is a targeted prodrug of tenofovir that was first approved by the FDA in 2016. In 2023, Vemlidy generated total worldwide sales of $862 million compared with 842 million in 2022.
Vemlidy 25 mg has a price of $1,528 for 30 tablets, according to Drugs.com. Patients with commercial insurance may be eligible for a $0 copay with an annual limit of $6,000 a year. Gilead notes in its terms and conditions that it may reduce or discontinue the copay assistance if a patient’s plan has a copay accumulator or maximizer program.
With accumulator programs, the money from copay cards does not count toward patients’ annual deductible or out-of-pocket limit. With maximizer programs, the copay assistance is evenly spread over the year but still doesn't count toward the deductible or out-of-pocket limit.
Vemlidy’s approval in the patient population is supported by week 96 data from a phase 2 clinical trial comparing treatment with Vemlidy 25 mg with placebo among 18 treatment-naïve and treatment-experienced patients aged 6 to less than 12 years. In the trial, 47 patients received Vemlidy and 23 received placebo. Patients in the Vemlidy group and in the placebo group who switched to open-label Vemlidy after week 24 demonstrated progressive increases in the rates of virological suppression through week 96 overall.
Most common adverse events in the children were: nasopharyngitis, headache, COVID-19, pyrexia, diarrhea, upper respiratory tract infection, cough, respiratory tract infection viral, and abdominal pain.
Vemlidy has a boxed warning in its product label about the risk of new or worsening renal impairment, the risk of HIV-1 resistance, and the risk of lactic acidosis.
FDA Approves Pfizer’s Gene Therapy for Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.